Rhythm Pharmaceuticals Inc RYTM

US Biotechnology

$98.66 ▲ +0.36% (+$0.35)

Open $98.41

Prev Close $98.31

Day Range $96.35 – $99.45

52W Range $74.50 – $122.20

Market Cap $6.79B

Beta 2.17

EPS (TTM) $-3.05

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2017-10-05
Shares Out.	68,530,000
Website	rhythmtx.com/ ↗
Phone	18009279800
Employees	414
Revenue	$71.3M
Gross Profit	$62.3M
Net Income	-$49.3M
Free Cash Flow	-$106.3M
Total Assets	$437.3M
Total Liabilities	$220.0M
Equity	$103.0M

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Rhythm Pharmaceuticals Inc is a publicly traded company under the ticker symbol RYTM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.